• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To register, simply click the Register button at the top right.

Peginterferon Lambda (IFN-λ) to treat Coxsackie/Enterovirus B


Senior Member
The new drug Peginterferon λ-1a (PEG-IFN-λ or PEG-IL-29), to treat chronic Echovirus and Coxsackievirus B.

Anyone want to try it w/ me? Let me know! (3 spots available)

The treatment in a nutshell...

Chronic Enterovirus B is usually in your gut (GI tract)*
  • Enteroviruses invade gut/intestinal mucosa, as this is a reservoir for viral persistence. The mucosa consists of epithelial cells
  • Enterovirus found in parietal cells of ME/CFS patients. (Parietal cells are epithelial cells)
  • Again, Enterovirus targets the gastrointestinal epithelium
  • GI Tract, or intestinal epithelium, or intestinal mucosa, all same thing
* even if you know you have chronic enterovirus b in places other than gut (e.g. brain, pancreas, heart), it still likely means you have the infection in your GI tract still as well.

(GI tract) Intestinal epithelial cells are infected
  • IEC (intestinal epithelial cells) – those in the GI tract (aka barrier, aka mucosa, aka epithelium etc)

GI tract secretes IFN to destroy infection

Enterovirus B eliminated successfully by IFN

but wait... Coxsackie BLOCKS IFN III (lambda)
  • But Coxsackie B evades host’s immune response in the intestine by preventing type I and III IFN expression in epithelial cells
  • CVB cleaves proteins in infected intestinal epithelial cells, blocking IFN III expression.
  • Thus, evading immune response

Peginterferon lambda (IFN III) to the rescue